FDA DRUG CENTER ESTABLISHING RECRUITMENT TASK FORCE
This article was originally published in The Tan Sheet
FDA DRUG CENTER ESTABLISHING RECRUITMENT TASK FORCE in response to delays in filing 40 vacant positions and the prospect of adding 300 more slots as user fee legislation is implemented. The concept of a "Recruitment Crisis Task Force" arose out of a Center for Drug Evaluation and Research "management retreat" in Warrenton, Va. on May 23-26. The task force, which has not yet been formed, is one of six initiatives outlined in a June 3 memo to all CDER employees from Director Carl Peck. As a first step to prepare for the new hires, a "tentative allocation" of the first 100 full-time equivalents (FTEs) has been made and a recruitment staff is being hired, CDER said June 10. These steps come as the Senate Appropriations Committee is pressuring the Clinton Administration to increase FDA staffing allowances to permit the agency to expand to the levels stipulated in the user fee law. The initial 100 slots are understood to include chemists, statisticians, toxicologists, consumer safety officers, microbiologists, computer specialists, pharmacokineticists, pharmacologists and medical officers. The center has prepared a recruitment package describing the positions and encouraging candidates to "join the organization that safeguards the drugs we take." Peck's June 3 memo calls on the task force to prepare a report "1) identifying division, center, and agency recruitment bottlenecks and short-term and long-term recommendations to eliminate them; 2) describing a clear, well-defined recruitment procedure with responsibility and accountability defined and measures to evaluate the success of the process; and 3) recommending recruitment strategies for hard-to-recruit disciplines." Peck has set a tight deadline of June 30 for the report. The memo calls on the task force to coordinate its efforts with the Center for Biologics Evaluation and Research and the User Fee Working Group and sets an Aug. 1 deadline for a decision by CDER and Senior Advisor to the Commissioner Mary Jo Veverka on the implementation of recommendations. The impetus for the task force comes at least in part from CDER's inability to comply swiftly with Office of Personnel Management guidelines on hiring procedures, according to one FDAer. Virtually no new hires were made between September and February as a result of this difficulty, the FDAer said. A General Accounting Office report submitted in August 1990 detailed widespread non-compliance among various agencies with federal law governing hiring procedures. The Office of Personnel Management responded to the study by issuing more specific instructions on documenting compliance. These instructions, FDAers said, have led to increased paperwork for CDER, causing the center to slip below its ceiling. As CDER attempts to resolve its staffing problems, user fee working groups continue to explore a range of implementation issues. The agency hopes to release its policy statement on combining market applications, or "bundling," and the definition of clinical data at the same time that it sends out invoices, since these issues have a direct bearing on the fees, FDA said June 11. FDAers have been predicting the imminent release of this guidance since February. Five other initiatives came out of the CDER management retreat and are outlined in Peck's June 3 memo: "Create Reviewer Affairs Committee to serve as a forum to communicate reviewers' concerns to upper management"; "Improve administrative/computer support at the reviewer level by charging a working group to make recommendations on what improvements should be made"; "Develop a Good Review Practices Document for clinical/statistical reviews"; "Create a broad-based project management implementation group . . . that will assist in the integration of project management techniques in the review divisions to enable the divisions to achieve the user fee performance goals"; And "re-examine relationships between the center and the field, addressing how to work together more constructively in improving integration of the review and inspection processes, communicating concerns, and resolving differences and misunderstandings."
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Sign in to continue reading.
Need a specific report?
1000+ reports available
New to Pink Sheet?
Start a free trial today!
Register for our free email digests: